Markets & Finance

Needham Keeps 'Strong Buy' on Dendreon


Needham reiterated his strong buy rating for Dendreon (DNDN

).

Analyst Mark Monane says data demonstrated Provenge's effect in the hardest-to-achieve clinical outcome (survival), and further validates the previous benefits seen with the vaccine in radiographic (time-to-disease progress), clinical (delay of bone pain onset), and immunological (T-cell proliferation) outcomes.

While Provenge (Phase 3, unpartnered) will likely not reach the market until the first quarter of 2006, he sees many events to stimulate investor interest over the next 6-to-12 months, including the completion of enrollment of another Provenge Phase 3 trial,and a marketing partnership for Provenge. He has a $15 12-month target.


Later, Baby
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

Sponsored Financial Commentaries

Sponsored Links

Buy a link now!

 
blog comments powered by Disqus